3.964
2.10%
-0.086
前日終値:
$4.05
開ける:
$4.03
24時間の取引高:
683.54K
Relative Volume:
0.70
時価総額:
$285.89M
収益:
$20.76M
当期純損益:
$-132.49M
株価収益率:
-1.3909
EPS:
-2.85
ネットキャッシュフロー:
$-108.55M
1週間 パフォーマンス:
-16.00%
1か月 パフォーマンス:
-36.56%
6か月 パフォーマンス:
-31.16%
1年 パフォーマンス:
+167.91%
C 4 Therapeutics Inc Stock (CCCC) Company Profile
CCCC を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
CCCC | 3.965 | 285.89M | 20.76M | -132.49M | -108.55M | -2.85 |
VRTX | 450.62 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 749.43 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.12 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 106.93 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-02-24 | アップグレード | Credit Suisse | Underperform → Neutral |
2023-02-24 | ダウングレード | JP Morgan | Neutral → Underweight |
2022-11-04 | ダウングレード | JP Morgan | Overweight → Neutral |
2022-10-11 | 開始されました | Morgan Stanley | Underweight |
2022-04-28 | 開始されました | Credit Suisse | Underperform |
2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
2022-03-10 | 開始されました | JP Morgan | Overweight |
2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
2021-11-23 | 開始されました | BofA Securities | Buy |
2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
2021-09-30 | 開始されました | Stifel | Hold |
2021-06-04 | 開始されました | H.C. Wainwright | Buy |
2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
2020-10-28 | 開始されました | UBS | Buy |
2020-10-27 | 開始されました | BMO Capital Markets | Outperform |
2020-10-27 | 開始されました | Jefferies | Buy |
すべてを表示
C 4 Therapeutics Inc (CCCC) 最新ニュース
C4 Therapeutics appoints Steve Hoerter to board - Investing.com
C4 Therapeutics appoints Steve Hoerter to board By Investing.com - Investing.com UK
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - The Bakersfield Californian
C4 Therapeutics Adds Oncology Veteran Steve Hoerter to Board, Brings Drug Launch Expertise | CCCC Stock News - StockTitan
C4 Therapeutics, Inc. Appoints Steve Hoerter as Board of Directors - Marketscreener.com
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Stephens Initiates Coverage on C4 Therapeutics (NASDAQ:CCCC) - MarketBeat
Stephens & Co. Initiates Coverage of C4 Therapeutics (CCCC) with Equal-Weight Recommendation - MSN
C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Large Drop in Short Interest - MarketBeat
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Orbimed Advisors LLC Increases Stake in C4 Therapeutics Inc - GuruFocus.com
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk - Simply Wall St
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout - Seeking Alpha
CCCCC4 Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial - The Manila Times
C4 Therapeutics Launches Phase 1 Trial in China: $357M Cancer Drug Partnership Advances | CCCC Stock News - StockTitan
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma At the American Society of Hematology Annual Meeting - Marketscreener.com
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting - The Manila Times
C4 Therapeutics' Cemsidomide Trial Data Selected for Key ASH Presentations in NHL, Myeloma | CCCC Stock News - StockTitan
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Will C4 Therapeutics' Upcoming Multiple Myeloma And NHL Trial Results Drive Stock Recovery? - RTTNews
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Advances in Protein Degradation Therapy - TipRanks
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates - MSN
C4 Therapeutics (CCCC) Q3 2024 Earnings: Revenue Surges to $15.4M, GAAP EPS Loss Narrows to $0.35 - GuruFocus.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
We're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash Wisely - Yahoo Finance
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizentribune
C4 Therapeutics appoints Paige Mahaney as new CSO - Investing.com India
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C 4 Therapeutics Inc (CCCC) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):